Emmaus Life Sciences Reports Annual Financial Results

Got story updates? Submit your updates here. ›

Emmaus Life Sciences, a biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases, has reported its annual financial results for the fiscal year ending December 31, 2025. The company highlighted key milestones and financial performance during the past year.

Why it matters

As a publicly traded biotech firm, Emmaus Life Sciences' financial performance and operational updates are closely watched by investors, analysts, and the broader pharmaceutical industry. The company's ability to develop and commercialize treatments for rare diseases is seen as an important part of addressing unmet medical needs.

The details

In its report, Emmaus Life Sciences noted that it achieved several key milestones in 2025, including the continued commercial rollout of its FDA-approved treatment for sickle cell disease. The company also highlighted progress in its pipeline of investigational therapies targeting other rare genetic disorders. From a financial perspective, Emmaus reported total revenues of $85 million for the fiscal year, a 12% increase over the prior year.

• Emmaus Life Sciences reported its annual financial results on March 30, 2026.
• The reported fiscal year ended on December 31, 2025.